HIMS Short squeeze still happening. I guess that's what happens to a stock with 33% short float that comes along with great numbers and guidance, dismissing the ghosts related with the end semaglutide shortage (which accounts for roughly 30% of rev). Still waiting for a good time to accumulate more shares...
HIMS my 2 cents on earnings. Beat top and bottom, which everyone likes to see. CF continues to grow, as well as subscriptions and $ per user. Opportunities within menopause and low testosterone products later this year, as well further partnerships with farmaceuticals (like Novo), without limiting the prescribed compounded products available. 2030 estimates for rev and ebitda growth will likely be met 2029 or earlier, just like the ones projected for 2024, which would imply 30% growth over the next years. Great stock to own, not a good day to buy. RSI got into overbought territory due to the short squeeze that's in motion. Cheers and take care everybody. FED meeting later this week.